表紙
市場調查報告書

新生抗原標靶藥物的全球市場

Neoantigen Targeted Therapies Market, 2019-2030

出版商 ROOTS ANALYSIS 商品編碼 853655
出版日期 內容資訊 英文 311 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
新生抗原標靶藥物的全球市場 Neoantigen Targeted Therapies Market, 2019-2030
出版日期: 2019年05月31日內容資訊: 英文 311 Pages
簡介

本報告提供全球新生抗原標靶藥物的市場調查,癌症免疫療法發展的過程,癌症免疫療法的限制,癌症免疫療法的新生抗原的重要性,新生抗原標靶藥物的已上市藥和開發平台趨勢,主要開發經營者的簡介,相關論文、專利分析,資金籌措、投資趨勢,適應症、新生抗原類型、免疫療法類型、投藥途徑、主要各地區/國家趨勢與市場規模的變化與預測,未來展望等資料彙整。

第1章 序論

第2章 摘要整理

第3章 簡介

  • 本章概要
  • 免疫療法的概念
  • 癌症免疫療法的發展的過程
  • 癌症免疫療法的限制
  • 對腫瘤新生抗原的標的
  • 主要課題、未來展望

第4章 市場概要

  • 本章概要
  • 新生抗原標靶藥物:已上市藥、開發平台
  • 開發平台分析:各種區分
  • 新生抗原標靶藥物:醫藥品開發業者清單:各種區分
  • 電網分析:各適應症、企業規模、所在地

第5章 企業簡介:新生抗原標靶藥物

  • 本章概要
  • Bavarian Nordic
  • Genocea Biosciences
  • Gradalis
  • Immunicum
  • Immunovative Therapies
  • Iovance Biotherapeutics
  • MediGene
  • Neon Therapeutics

第6章 論文分析

  • 本章概要
  • 論文清單:各種區分

第7章 專利分析

  • 本章概要
  • 調查範圍、調查手法
  • 新生抗原標靶藥物:專利分析:各種區分
  • 新生抗原標靶藥物:專利基準分析
  • 新生抗原標靶藥物:專利評估分析

第8章 聯盟、合作

  • 本章概要
  • 聯盟模式
  • 聯盟、合作清單:各種區分

第9章 資金籌措、投資分析

  • 本章概要
  • 資金類型
  • 資金籌措、投資分析:各種區分
  • 總論

第10章 市場預測、市場機會分析

  • 本章概要
  • 前提條件、預測手法
  • 全球市場的預測
    • 各地區
    • 各適應症
      • 骨軟骨腫瘤
      • 大腸癌
      • 婦產科系癌症
      • 頭頸椎癌症
      • 肝癌
      • 肺癌
      • 腎癌症
      • 其他
    • 各新生抗原類型
      • 個體化新生抗原標靶藥物
      • 既成新生抗原標靶藥物
    • 各免疫療法類型
      • 樹突狀細胞疫苗
      • DNA/RNA為基礎的疫苗
      • 蛋白質/肽為基礎的疫苗
      • TIL為基礎的治療藥
    • 各投藥途徑
      • 皮內注射
      • 靜脈注射
      • 皮下注射
      • 其他
  • 美國市場的預測
  • 英國市場預測
  • 德國市場預測
  • 法國市場預測
  • 義大利市場預測
  • 西班牙市場預測
  • 其他地區

第11章 總論

第12章 專家的見解

  • 本章概要
  • AIVITA Biomedical
  • BioLineRx
  • VAXIMM

第13章 附錄1:圖表資料

第14章 附錄2:企業、組織清單

目錄

Example Insights:

The increasing traction in this field is also reflected in the partnership activity; deals inked in the recent past focused on a diverse range of therapies, involving both international and indigenous stakeholders.

Overview:

Cancer is known to be one of the leading causes of death worldwide, accounting for 0.6 million deaths in 2018, in the US alone. The World Health Organization has estimated the number of new cancer cases, reported across the globe, to rise by 70% over the next 20 years. Conventional treatment options, such as chemotherapy, surgery and radiation therapy, continue to demonstrate limited efficacy in late-stage cancers. Moreover, the non-specific and highly toxic nature of chemotherapy and radiation therapy, have severe detrimental effects on patients' quality of life. Amongst the targeted anti-cancer therapies, immunotherapy has emerged as a potent option, capable of eliminating tumor cells with minimal side effects. For instance, the introduction of the immune check point inhibitors (such as PD-1/PD-L1 and CTLA-4 inhibitors) enabled healthcare providers to offer long term clinical benefit to patients suffering from metastatic tumors. However, these therapies have been reported to generate variable / inconsistent immune responses across different patients and, as a result, only a fraction of patients have actually ended up benefiting from such treatments. In fact, it is estimated that close to 70% of treated patients do not respond to single-agent immune checkpoint therapy.

Recent developments in genomic analysis and advances in bioinformatics have enabled the adoption of more personalized treatment approaches, such as neoantigen targeted therapies. Cancer neoantigens is a term used to refer to a subset of antigens encoded by tumor-specific, mutated genes, which have not previously been recognized by host's immune system. These are considered to be potential biological targets that can be used to augment the therapeutic value of a number of cancer immunotherapies, including immune checkpoint inhibitors and cancer vaccines, having demonstrated the capability to elicit strong T-cell mediated immune response. Currently, several neoantigen-based therapies are being investigated in combination with various immune checkpoint inhibitors, such as atezolizumab, durvalumab, ipilimumab and nivolumab. In fact, multiple such initiatives by start-ups are backed by venture capital firms and other strategic investors.

Scope of the Report:

The “Neoantigen Targeted Therapies Market, 2019-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape, providing information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, type of molecule (small molecule and biologic), type of treatment (personalized and off-the-shelf), type of therapy (monotherapy and combination therapy), type of immunotherapy, target indication, line of treatment, and route of administration of the drugs / therapies that are being developed for the treatment of cancer.
  • Detailed profiles of developers of neoantigen targeted therapies (shortlisted on the basis of the number of pipeline products), featuring an overview of the company, its financial information (if available), a detailed description of its product portfolio and recent collaborations. In addition, each profile includes an informed future outlook.
  • A detailed publication analysis of close to 300 peer-reviewed, scientific articles published during the period 2015-2019 (till February), highlighting the research focus within the industry. It also highlights the key trends observed across the publications, including information on target disease indications, affiliated cancer immunotherapies, and analysis based on various relevant parameters, such as study type (review article, research article and meta-analysis), year of publication, and most popular journals (in terms of number of articles published in the given time period) within this domain.
  • An in-depth analysis of the various patents that have been filed / granted related to neoantigens till April 2019. It includes information on key parameters, such as patent type, publication year, issuing authority, assigned CPC symbol, emerging focus areas and leading industry / academic players(in terms of size of intellectual property portfolio).
  • An analysis of the various partnerships pertaining to neoantigen targeting therapies, which have been established till March 2019, based on various parameters, such as the type of partnership, year of partnership, target disease indications, type of immunotherapy and the most active players.
  • An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are focused on developing neoantigen targeted therapies.

One of the key objectives of the report was to estimate the existing market size and the future opportunity for neoantigen targeted therapies, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of neoantigen targeted therapies and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2019-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] different target indications (bone and cartilage cancer, colorectal cancer, head and neck cancer, renal carcinoma, hepatocellular carcinoma, lung cancer, gynecological cancer and others) [B] type of treatment (personalized and off-the-shelf), [C] type of immunotherapy (dendritic cell vaccine, DNA / RNA-based vaccine, protein / peptide-based vaccine and TIL-based therapy), [D] route of administration (intradermal, intravenous, subcutaneous, and others) and [E] key geographical regions (US, EU5 and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names):

  • Gabriel Nistor (Chief Scientific Officer, AIVITA Biomedical)
  • Ella Sorani (Vice President Research and Development, BioLineRx)
  • Heinz Lubenau (Chief Operating Officer and Co-Founder, VAXIMM)

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the state of the market for neoantigen targeted therapies, in the short-mid term and long term.

Chapter 3 provides a general overview of neoantigen targeted therapies, featuring brief descriptions of the various conventional forms of therapy that are used for the treatment of oncological disorders. It also includes a discussion on the advent and evolution of cancer immunotherapy, while highlighting its limitations. The chapter lays emphasis on the role of neoantigens in cancer immunotherapy, providing details on the various types of neoantigens, product development-related aspects of neoantigen targeted therapies and the diverse strategies that are available / being investigated for delivery of neoantigen-based therapeutics.

Chapter 4 includes information on nearly 150 molecules that are currently under development for the treatment of various cancer indications. It features a comprehensive analysis of pipeline molecules, highlighting phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, type of molecule (small molecule and biologic), type of treatment (personalized and off-the-shelf), type of therapy (monotherapy and combination therapy), type of immunotherapy, target indication, line of treatment, and route of administration of the drugs / therapies that are being developed for the treatment of cancer. In addition, the chapter provides information on drug developer(s), highlighting year of their establishment, location of headquarters and employee strength.

Chapter 5 provides detailed profiles of some of the leading stakeholders in this field (shortlisted on the basis of number of pipeline products). Each profile presents a brief overview of the company, its financial information (if available), product portfolio, recent collaborations and an informed future outlook.

Chapter 6 provides a detailed analysis of close to 300 research articles related to neoantigen targeted therapies, published in the period 2015-2019 (till February). The analysis takes into consideration several aspects, namely target disease indications, affiliated cancer immunotherapies, and analysis based on various relevant parameters, such as study type (review article, research article and meta-analysis), year of publication, and most popular journals (in terms of number of articles published in the given time period), within this domain.

Chapter 7 provides an in-depth patent analysis, presenting an overview on the filed / granted patents related to neoantigens. For this analysis, we looked at the patents that have been published by various players, till April 2019. The analysis highlights key details and trends associated with these patents, including patent type (granted patents, patent applications and others), publication year, patent issuing authorities / patent offices (USPTO, WIPO, APO, EPO and others), CPC classification, emerging focus areas and the leading industry / academic players. The chapter also includes a patent benchmarking analysis and a detailed valuation analysis.

Chapter 8 features an elaborate analysis and discussion on the various collaborations and partnerships that have been inked amongst stakeholders in this domain, since 2014. It includes a brief description of various types of partnership models (namely acquisitions, licensing agreements, product development and commercialization agreements, research agreements, distribution and supply agreements, service alliances and other agreements) that have been adopted by stakeholders in this domain. It also includes a schematic representation that showcases the companies that have established the maximum number of alliances, highlighting most popular therapies and disease indications.

Chapter 9 presents details on various investments received by the start-ups / smaller companies that are engaged in this domain. It also includes an analysis of the funding instances that have taken place in the market, till April 2019, highlighting the growing interest of the venture capital community and other strategic investors within this market.

Chapter 10 features a detailed market forecast analysis, highlighting the likely growth of neoantigen targeted therapies till the year 2030. We have provided inputs on the likely distribution of the opportunity based on different target indications (bone and cartilage cancer, colorectal cancer, head and neck cancer, renal carcinoma, hepatocellular carcinoma, lung cancer, gynecological cancer and others), type of treatment (personalized and off-the-shelf), type of immunotherapy (dendritic cell vaccine, DNA / RNA-based vaccine, protein / peptide-based vaccine and TIL-based therapy), route of administration (intradermal, intravenous, subcutaneous, and others) and key geographical regions (US, EU5 and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Chapter 11 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the neoantigen targeted therapies industry.

Chapter 12 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with (in alphabetical order of company name) Gabriel Nistor (Chief Scientific Officer, AIVITA Biomedical), Ella Sorani (Vice President Research and Development, BioLineRx) and Heinz Lubenau (Chief Operating Officer and Co-Founder, VAXIMM).

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 14 is an appendix, which contains a list of companies and organizations mentioned in this report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Concept of Immunotherapy
  • 3.3. History of Cancer Immunotherapy
  • 3.4. Limitations of Cancer Immunotherapy
  • 3.5. Targeting Tumor-Specific Neoantigens
    • 3.5.1. Types of Neoantigens
    • 3.5.2. Role of Neoantigens in Cancer Immunotherapy
    • 3.5.3. Neoantigen Targeted Therapies
      • 3.5.3.1. Identification and Selection of Neoantigens
      • 3.5.3.2. Delivery of Neoantigen Targeted Therapies
  • 3.6. Key Challenges and Future Perspectives

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Neoantigen Targeted Therapies: Marketed and Development Pipeline
  • 4.3. Neoantigen Targeted Therapies: Pipeline Analysis
    • 4.3.1. Analysis by Phase of Development
    • 4.3.2. Analysis by Type of Molecule
    • 4.3.3. Analysis by Type of Immunotherapy
    • 4.3.4. Analysis by Type of Therapy
    • 4.3.5. Analysis by Route of Administration
    • 4.3.6. Analysis by Target Disease Indication
    • 4.3.7. Analysis by Type of Neoantigen
    • 4.3.8. Analysis by Line of Therapy
    • 4.3.9. Funnel Analysis: Analysis by Phase of Development, Type of Immunotherapy and Type of Therapy
    • 4.3.10. Heptagon Representation: Analysis by Phase of Development and Route of Administration
  • 4.4. Neoantigen Targeted Therapies: List of Drug Developers
    • 4.4.1. Analysis by Year of Establishment
    • 4.4.2. Analysis by Company Size and Geographical Location
    • 4.4.3. Leading Developers
    • 4.4.4. Analysis by Geography
  • 4.5. Grid Analysis: Analysis by Target Disease Indication, Company Size and Location

5. COMPANY PROFILES: NEOANTIGEN TARGETED THERAPIES

  • 5.1. Chapter Overview
  • 5.2. Bavarian Nordic
    • 5.2.1. Company Overview
    • 5.2.2. Financial Information
    • 5.2.3. Neoantigen Targeted Therapies Portfolio
    • 5.2.4. Recent Collaborations
    • 5.2.5. Future Outlook
  • 5.3. Genocea Biosciences
    • 5.3.1. Company Overview
    • 5.3.2. Financial Information
    • 5.3.3. Neoantigen Targeted Therapies Portfolio
    • 5.3.4. Recent Collaborations
    • 5.3.5. Future Outlook
  • 5.4. Gradalis
    • 5.4.1. Company Overview
    • 5.4.2. Neoantigen Targeted Therapies Portfolio
    • 5.4.3. Recent Collaborations
    • 5.4.4. Future Outlook
  • 5.5. Immunicum
    • 5.5.1. Company Overview
    • 5.5.2. Financial Information
    • 5.5.3. Neoantigen Targeted Therapies Portfolio
    • 5.5.4. Recent Collaborations
    • 5.5.5. Future Outlook
  • 5.6. Immunovative Therapies
    • 5.6.1. Company Overview
    • 5.6.2. Neoantigen Targeted Therapies Portfolio
    • 5.6.3. Recent Collaborations
    • 5.6.4. Future Outlook
  • 5.7. Iovance Biotherapeutics
    • 5.7.1. Company Overview
    • 5.7.2. Financial Information
    • 5.7.3. Neoantigen Targeted Therapies Portfolio
    • 5.7.4. Recent Collaborations
    • 5.7.5. Future Outlook
  • 5.8. MediGene
    • 5.8.1. Company Overview
    • 5.8.2. Financial Information
    • 5.8.3. Neoantigen Targeted Therapies Portfolio
    • 5.8.4. Recent Collaborations
    • 5.8.5. Future Outlook
  • 5.9. Neon Therapeutics
    • 5.9.1. Company Overview
    • 5.9.2. Financial Information
    • 5.9.3. Neoantigen Targeted Therapies Portfolio
    • 5.9.4. Recent Collaborations
    • 5.9.5. Future Outlook

6. PUBLICATION ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Methodology
  • 6.3. Neoantigen Targeted Therapies: List of Publications
    • 6.3.1. Analysis by Year of Publication
    • 6.3.2. Analysis by Type of Study
    • 6.3.3. Analysis by Study Objective
    • 6.3.4. Analysis by Affiliated Therapies
    • 6.3.5. Analysis by Target Disease Indication
    • 6.3.6. Key Journals: Analysis by Number of Publications

7. PATENT ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Scope and Methodology
  • 7.3. Neoantigen Targeted Therapies: Patent Analysis
    • 7.3.1. Analysis by Publication Year
    • 7.3.2. Analysis by Geographical Location
    • 7.3.3. Analysis by CPC Classifications
    • 7.3.4. Analysis by Type of Industry
    • 7.3.5. Emerging Focus Areas
    • 7.3.6. Leading Players: Analysis by Number of Patents
  • 7.4. Neoantigen Targeted Therapies: Patent Benchmarking Analysis
    • 7.4.1. Analysis by Patent Characteristics
  • 7.5. Neoantigen Targeted Therapies: Patent Valuation Analysis

8. PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. Neoantigen Targeted Therapies: List of Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Type of Immunotherapy
    • 8.3.4. Analysis by Type of Partnership and Type of Product
    • 8.3.5. Analysis by Type of Partnership and Target Disease Indication
    • 8.3.6. Regional Analysis
    • 8.3.7. Most Active Players: Analysis by Number of Partnerships

9. FUNDING AND INVESTMENT ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Types of Funding
  • 9.3. Neoantigen Targeted Therapies: Funding and Investment Analysis
    • 9.3.1. Analysis by Number of Instances
    • 9.3.2. Analysis by Amount Invested
    • 9.3.3. Analysis by Type of Funding
    • 9.3.4. Analysis by Amount Invested across Different Types of Therapies
    • 9.3.5. Analysis by Amount Invested across Different Types of Indications
    • 9.3.4. Analysis by Geography
    • 9.3.5. Most Active Players: Analysis by Amount of Funding
    • 9.3.6. Most Active Investors: Analysis by Number of Instances
  • 9.4. Concluding Remarks

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 10.1 Chapter Overview
  • 10.2. Key Assumptions and Forecast Methodology
  • 10.3. Global Neoantigen Targeted Therapies Market, 2019-2030
    • 10.3.1. Global Neoantigen Targeted Therapies Market: Distribution by Region, 2019-2030 (USD Million)
    • 10.3.2. Global Neoantigen Targeted Therapies Market: Distribution by Target Disease Indication, 2019-2030 (USD Million)
      • 10.3.2.1. Global Neoantigen Targeted Therapies Market for Bone and Cartilage Cancer, 2019-2030 (USD Million)
      • 10.3.2.2. Global Neoantigen Targeted Therapies Market for Colorectal Cancer, 2019-2030
      • 10.3.2.3. Global Neoantigen Targeted Therapies Market for Gynecological Cancers, 2019-2030 (USD Million)
      • 10.3.2.4. Global Neoantigen Targeted Therapies Market for Head and Neck Cancer, 2019-2030 (USD Million)
      • 10.3.2.5. Global Neoantigen Targeted Therapies Market for Hepatocellular Carcinoma, 2019-2030 (USD Million)
      • 10.3.2.6. Global Neoantigen Targeted Therapies Market for Lung Cancer, 2019-2030 (USD Million)
      • 10.3.2.7. Global Neoantigen Targeted Therapies Market for Renal Carcinoma, 2019-2030 (USD Million)
      • 10.3.2.8. Global Neoantigen Targeted Therapies Market for Other Cancers, 2019-2030 (USD Million)
    • 10.3.3. Global Neoantigen Targeted Therapies Market: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
      • 10.3.3.1. Global Neoantigen Targeted Therapies Market for Personalized Neoantigen Targeted Therapies, 2019-2030 (USD Million)
      • 10.3.3.2. Global Neoantigen Targeted Therapies Market for Off-the-shelf Neoantigen Targeted Therapies, 2019-2030 (USD Million)
    • 10.3.4. Global Neoantigen Targeted Therapies Market: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
      • 10.3.4.1. Global Neoantigen Targeted Therapies Market for Dendritic Cell Vaccines, 2019-2030 (USD Million)
      • 10.3.4.2. Global Neoantigen Targeted Therapies Market for DNA / RNA-based Vaccines, 2019-2030 (USD Million)
      • 10.3.4.3. Global Neoantigen Targeted Therapies Market for Protein / Peptide-based Vaccines, 2019-2030 (USD Million)
      • 10.3.4.4. Global Neoantigen Targeted Therapies Market for TIL-based Therapies, 2019-2030 (USD Million)
    • 10.3.5. Global Neoantigen Targeted Therapies Market: Distribution by Route of Administration, 2019-2030 (USD Million)
      • 10.3.5.1. Global Neoantigen Targeted Therapies Market for Intradermal Route of Administration, 2019-2030 (USD Million)
      • 10.3.5.2. Global Neoantigen Targeted Therapies Market for Intravenous Route of Administration, 2019-2030 (USD Million)
      • 10.3.5.3. Global Neoantigen Targeted Therapies Market for Subcutaneous Route of Administration, 2019-2030 (USD Million)
      • 10.3.5.4. Global Neoantigen Targeted Therapies Market for Other Routes of Administration, 2019-2030 (USD Million)
  • 10.4. Neoantigen Targeted Therapies Market in the US, 2019-2030 (USD Million)
    • 10.4.1. Neoantigen Targeted Therapies Market in the US: Distribution by Target Disease Indication, 2019-2030 (USD Million)
    • 10.4.2. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
    • 10.4.3. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
    • 10.4.3. Neoantigen Targeted Therapies Market in the US: Distribution by Route of Administration, 2019-2030 (USD Million)
  • 10.5. Neoantigen Targeted Therapies Market in the UK, 2019-2030 (USD Million)
    • 10.5.1. Neoantigen Targeted Therapies Market in the UK: Distribution by Target Disease Indication, 2019-2030 (USD Million)
    • 10.5.2. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
    • 10.5.3. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
    • 10.5.4. Neoantigen Targeted Therapies Market in the UK: Distribution by Route of Administration, 2019-2030 (USD Million)
  • 10.6. Neoantigen Targeted Therapies Market in Germany, 2019-2030 (USD Million)
    • 10.6.1. Neoantigen Targeted Therapies Market in Germany: Distribution by Target Disease Indication, 2019-2030 (USD Million)
    • 10.6.2. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
    • 10.6.3. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
    • 10.6.4. Neoantigen Targeted Therapies Market in Germany: Distribution by Route of Administration, 2019-2030 (USD Million)
  • 10.7. Neoantigen Targeted Therapies Market in France, 2019-2030 (USD Million)
    • 10.7.1. Neoantigen Targeted Therapies Market in France: Distribution by Target Disease Indication, 2019-2030 (USD Million)
    • 10.7.2. Neoantigen Targeted Therapies Market in France: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
    • 10.7.3. Neoantigen Targeted Therapies Market in France: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
    • 10.7.4. Neoantigen Targeted Therapies Market in France: Distribution by Route of Administration, 2019-2030 (USD Million)
  • 10.8. Neoantigen Targeted Therapies Market in Italy, 2019-2030 (USD Million)
    • 10.8.1. Neoantigen Targeted Therapies Market in Italy: Distribution by Target Disease Indication, 2019-2030 (USD Million)
    • 10.8.2. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
    • 10.8.3. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
    • 10.8.4. Neoantigen Targeted Therapies Market in Italy: Distribution by Route of Administration, 2019-2030 (USD Million)
  • 10.9. Neoantigen Targeted Therapies Market in Spain, 2019-2030 (USD Million)
    • 10.9.1. Neoantigen Targeted Therapies Market in Spain: Distribution by Target Disease Indication, 2019-2030 (USD Million)
    • 10.9.2. Neoantigen Targeted Therapies Market in Spain: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
    • 10.9.3. Neoantigen Targeted Therapies Market in Spain: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
    • 10.9.4. Neoantigen Targeted Therapies Market in Spain: Distribution by Route of Administration, 2019-2030 (USD Million)
  • 10.10. Neoantigen Targeted Therapies Market in Rest of the World, 2019-2030 (USD Million)
    • 10.10.1. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Target Disease Indication, 2019-2030 (USD Million)
    • 10.10.2. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
    • 10.10.3. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
    • 10.10.4. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Route of Administration, 2019-2030 (USD Million)

11. CONCLUDING REMARKS

12. EXECUTIVE INSIGHTS

  • 12.1. Chapter Overview
  • 12.2. AIVITA Biomedical
    • 12.2.1. Company Snapshot
    • 12.2.2. Interview Transcript: Gabriel Nistor (Chief Scientific Officer)
  • 12.3. BioLineRx
    • 12.3.1. Company Snapshot
    • 12.3.2. Interview Transcript: Ella Sorani (Vice President Research and Development)
  • 12.3. VAXIMM
    • 12.3.1. Company Snapshot
    • 12.3.2. Interview Transcript: Heinz Lubenau (Chief Operating Officer and Co-Founder)

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

  • Figure 3.1. Global Age-Standardized Incidence Rates of Cancer in 2018 (per 100,000
  • Figure 3.2. Four Pillars of Cancer Therapy
  • Figure 3.3. Evolution of Cancer Immunotherapy
  • Figure 3.4. Limitations of Cancer Immunotherapy
  • Figure 3.5. Personalized and Off-the-shelf Neoantigens
  • Figure 3.6. Next Generation Sequencing of Neoantigens: Process Steps
  • Figure 4.1. Neoantigen Targeted Therapies: Distribution by Phase of Development
  • Figure 4.2. Neoantigen Targeted Therapies: Distribution by Type of Molecule
  • Figure 4.3. Neoantigen Targeted Therapies: Distribution by Type of Immunotherapy
  • Figure 4.4. Neoantigen Targeted Therapies: Distribution by Type of Therapy
  • Figure 4.5. Neoantigen Targeted Therapies: Distribution by Route of Administration
  • Figure 4.6. Neoantigen Targeted Therapies: Distribution by Target Disease Indication
  • Figure 4.7. Neoantigen Targeted Therapies: Distribution by Type of Neoantigen
  • Figure 4.8. Neoantigen Targeted Therapies: Distribution by Line of Therapy
  • Figure 4.9. Funnel Analysis: Distribution by Phase of Development, Type of Immunotherapy and Type of Therapy
  • Figure 4.10. Heptagon Representation: Distribution by Phase of Development and Route of Administration
  • Figure 4.11. Neoantigen Targeted Therapy: Distribution by Year of Establishment of Developer
  • Figure 4.12. Neoantigen Targeted Therapies: Distribution by Company Size and Geographical Location
  • Figure 4.13. Leading Developers: Distribution by Number of Therapies
  • Figure 4.14. Neoantigen Targeted Therapies: Distribution by Geographical Location of Developer
  • Figure 4.15. Grid Analysis: Distribution by Target Disease Indication, Company Size and Location
  • Figure 5.1. Bavarian Nordic: Annual Revenues, FY2014-FY2018 (DKK Million)
  • Figure 5.2. Medigene: Annual Revenues, FY2014-FY2018 (EUR Million)
  • Figure 6.1. Publications: Distribution by Year of Publication
  • Figure 6.2. Publications: Distribution by Type of Study
  • Figure 6.3. Publications: Distribution by Study Objective
  • Figure 6.4. Publications: Distribution by Affiliated Therapies
  • Figure 6.5. Publications: Distribution by Target Disease Indication
  • Figure 6.6. Key Journals: Distribution by Number of Publications
  • Figure 7.1. Patent Analysis: Distribution by Type of Patent
  • Figure 7.2. Patent Analysis: Cumulative Distribution by Publication Year, Pre2010-2019
  • Figure 7.3. Patent Analysis: Distribution by Geographical Location
  • Figure 7.4. Patent Analysis: Distribution by Geographical Location, 2000-2009 and 2010-2019
  • Figure 7.5. Patent Analysis: Distribution by CPC Classification Symbols
  • Figure 7.6. Patent Analysis: Emerging Focus Areas
  • Figure 7.7. Patent Analysis: Distribution by Type of Applicant
  • Figure 7.8. Leading Industry Players: Distribution by Number of Patents
  • Figure 7.9. Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 7.10. Leading Individual Assignees: Distribution by Number of Patents
  • Figure 7.11. Patent Analysis: Benchmarking by Patent Characteristics
  • Figure 7.12. Patent Analysis: Distribution by Patent Age (January 2000 - April 2019)
  • Figure 7.13. Patent Analysis: Valuation Analysis
  • Figure 8.1. Partnerships and Collaborations: Cumulative Trend by Year, 2014-2019
  • Figure 8.2. Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 8.3. Partnerships and Collaborations: Distribution by Type of Partnership, 2014-2016 and 2017-2019
  • Figure 8.4. Partnerships and Collaborations: Distribution by Type of Product
  • Figure 8.5. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Immunotherapy
  • Figure 8.6. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Target Disease Indication
  • Figure 8.7. Most Active Players: Distribution by Number of Partnerships
  • Figure 8.8. Partnership and Collaborations: Regional Distribution
  • Figure 8.9. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Figure 9.1. Distribution by Type of Funding and Year of Establishment of Company, 2014-2019
  • Figure 9.2. Funding and Investment Analysis: Cumulative Number of Instances by Year, 2014-2019
  • Figure 9.3. Funding and Investment Analysis: Distribution by Type of Funding and Year,
  • Figure 9.4. Funding and Investment Analysis: Cumulative Amount Invested, 2014-2019 (USD Million)
  • Figure 9.5. Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2014-2019
  • Figure 9.6. Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, 2014-2019 (USD Million)
  • Figure 9.7. Funding and Investment Analysis: Summary of Investments, 2014-2019 (USD Million)
  • Figure 9.8. Funding and Investments: Analysis by Amount Invested across Different Types of Therapies
  • Figure 9.9. Funding and Investment Analysis: Distribution by Amount Invested across Different Types of Indications
  • Figure 9.10. Funding and Investment Analysis: Distribution by Geography
  • Figure 9.11. Most Active Players: Distribution by Amount Invested (USD Million)
  • Figure 9.12. Most Active Investors: Distribution by Number of Instances
  • Figure 9.13. Funding and Investment Summary, 2014-2019 (USD Million)
  • Figure 10.1. Global Neoantigen Targeted Therapies Market, 2019-2030 (USD Million)
  • Figure 10.2. Global Neoantigen Targeted Therapies Market Distribution by Region, 2019-2030 (USD Million)
  • Figure 10.3. Global Neoantigen Targeted Therapies Market: Distribution by Target Disease Indication, 2019-2030 (USD Million)
  • Figure 10.4. Global Neoantigen Targeted Therapies Market for Bone and Cartilage Cancer, 2019-2030 (USD Million)
  • Figure 10.5. Global Neoantigen Targeted Therapies Market for Colorectal Cancer, 2019-2030 (USD Million)
  • Figure 10.6. Global Neoantigen Targeted Therapies Market for Gynecological Cancers, 2019-2030 (USD Million)
  • Figure 10.7. Global Neoantigen Targeted Therapies Market for Head and Neck Cancer, 2019-2030 (USD Million)
  • Figure 10.8. Global Neoantigen Targeted Therapies Market for Hepatocellular Carcinoma, 2019-2030 (USD Million)
  • Figure 10.9. Global Neoantigen Targeted Therapies Market for Lung Cancer, 2019-2030 (USD Million)
  • Figure 10.10. Global Neoantigen Targeted Therapies Market for Renal Carcinoma, 2019-2030 (USD Million)
  • Figure 10.11. Global Neoantigen Targeted Therapies Market for Other Cancers, 2019-2030 (USD Million)
  • Figure 10.12. Global Neoantigen Targeted Therapies Market: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
  • Figure 10.13. Global Neoantigen Targeted Therapies Market for Personalized Neoantigen Therapy, 2019-2030 (USD Million)
  • Figure 10.14. Global Neoantigen Targeted Therapies Market for Off-the-shelf Neoantigen Therapy, 2019-2030 (USD Million)
  • Figure 10.15. Global Neoantigen Targeted Therapies Market: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
  • Figure 10.16. Global Neoantigen Targeted Therapies Market for Dendritic Cell Vaccines, 2019-2030 (USD Million)
  • Figure 10.17. Global Neoantigen Targeted Therapies Market for DNA / RNA-based Vaccines, 2019-2030 (USD Million)
  • Figure 10.18. Global Neoantigen Targeted Therapies Market for Protein / Peptide-based Vaccine, 2019-2030 (USD Million)
  • Figure 10.19. Global Neoantigen Targeted Therapies Market for TIL-based Therapies, 2019-2030 (USD Million)
  • Figure 10.20. Global Neoantigen Targeted Therapies Market: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Figure 10.21. Global Neoantigen Targeted Therapies Market for Intradermal Route of Administration, 2019-2030 (USD Million)
  • Figure 10.22. Global Neoantigen Targeted Therapies Market for Intravenous Route of Administration, 2019-2030 (USD Million)
  • Figure 10.23. Global Neoantigen Targeted Therapies Market for Subcutaneous Route of Administration, 2019-2030 (USD Million)
  • Figure 10.24. Global Neoantigen Targeted Therapies Market for Others Route of Administration, 2019-2030 (USD Million)
  • Figure 10.25. Neoantigen Targeted Therapies Market in the US, 2019-2030 (USD Million)
  • Figure 10.26. Neoantigen Targeted Therapies Market in the US: Distribution by Target Disease Indication, 2019-2030 (USD Million)
  • Figure 10.27. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
  • Figure 10.28. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
  • Figure 10.29. Neoantigen Targeted Therapies Market in the US: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Figure 10.30. Neoantigen Targeted Therapies Market in the UK, 2019-2030 (USD Million)
  • Figure 10.31. Neoantigen Targeted Therapies Market in the UK: Distribution by Target Disease Indication, 2019-2030 (USD Million)
  • Figure 10.32. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
  • Figure 10.33. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
  • Figure 10.34. Neoantigen Targeted Therapies Market in the UK: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Figure 10.35. Neoantigen Targeted Therapies Market in Germany, 2019-2030 (USD Million)
  • Figure 10.36. Neoantigen Targeted Therapies Market in Germany: Distribution by Target Disease Indication, 2019-2030 (USD Million)
  • Figure 10.37. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
  • Figure 10.38. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
  • Figure 10.39. Neoantigen Targeted Therapies Market in Germany: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Figure 10.40. Neoantigen Targeted Therapies Market in France, 2019-2030 (USD Million)
  • Figure 10.41. Neoantigen Targeted Therapies Market in France: Distribution by Target Disease Indication, 2019-2030 (USD Million)
  • Figure 10.42. Neoantigen Targeted Therapies Market in France: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
  • Figure 10.43. Neoantigen Targeted Therapies Market in France: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
  • Figure 10.44. Neoantigen Targeted Therapies Market in France: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Figure 10.45. Neoantigen Targeted Therapies Market in Italy, 2019-2030 (USD Million)
  • Figure 10.46. Neoantigen Targeted Therapies Market in Italy: Distribution by Target Disease Indication, 2019-2030 (USD Million)
  • Figure 10.47. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
  • Figure 10.48. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
  • Figure 10.49. Neoantigen Targeted Therapies Market in Italy: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Figure 10.50. Neoantigen Targeted Therapies Market in Spain, 2019-2030 (USD Million)
  • Figure 10.51. Neoantigen Targeted Therapies Market in Spain: Distribution by Target Disease Indication, 2019-2030 (USD Million)
  • Figure 10.52. Neoantigen Targeted Therapies Market in Spain: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
  • Figure 10.53. Neoantigen Targeted Therapies Market in Spain: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
  • Figure 10.54. Neoantigen Targeted Therapies Market in Spain: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Figure 10.55. Neoantigen Targeted Therapies Market in Rest of the World, 2019-2030 (USD Million)
  • Figure 10.56. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Target Disease Indication, 2019-2030 (USD Million)
  • Figure 10.57. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
  • Figure 10.58. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
  • Figure 10.59. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Route of Administration, 2019-2030 (USD Million)

List of Tables

  • Table 3.1. Difference between Personalized and Off-the-shelf Neoantigens
  • Table 3.2. List of Neoantigen Targeted Combination Therapies
  • Table 3.3. List of Algorithms Used for Neoantigen Prediction
  • Table 3.4. Delivery Strategies for Neoantigen Therapies
  • Table 4.1. Neoantigen Targeted Therapies: Marketed and Development Pipeline
  • Table 4.2. Neoantigen Targeted Therapies: List of Companies
  • Table 5.1. Bavarian Nordic: Company Snapshot
  • Table 5.2. Drug Profile: CV301
  • Table 5.3. Drug Profile: BN-Brachyury
  • Table 5.4. Bavarian Nordic: Future Outlook
  • Table 5.5. Genocea Biosciences: Company Snapshot
  • Table 5.6. Drug Profile: GEN-009
  • Table 5.7. Genocea Biosciences: Future Outlook
  • Table 5.8. Genocea Biosciences: Company Snapshot
  • Table 5.9. Drug Profile: Vigil®
  • Table 5.10. Future Outlook
  • Table 5.11. Immunicum: Company Snapshot
  • Table 5.12. Drug Profile: Ilixadencel
  • Table 5.13. Immunicum: Future Outlook
  • Table 5.14. Immunovative Therapies: Company Snapshot
  • Table 5.15. Drug Profile: Chaperone Rich Cell Lysate
  • Table 5.16. Drug Profile: AlloStim®
  • Table 5.17. Drug Profile: AlloVax®
  • Table 5.18. Immunovative Therapies: Future Outlook
  • Table 5.19. Iovance Biotherapeutics: Company Snapshot
  • Table 5.20. Drug Profile: Lifileucel (LN-144)
  • Table 5.21. Drug Profile: LN-145
  • Table 5.22. Drug Profile: MDA TIL
  • Table 5.23. Iovance Biotherapeutics: Future Outlook
  • Table 5.24. MediGene: Company Snapshot
  • Table 5.25. Drug Profile: WT1 / PRAME
  • Table 5.26. Drug Profile: MDG1011
  • Table 5.27. MediGene: Future Outlook
  • Table 5.28. Neon Therapeutics: Company Snapshot
  • Table 5.29. Drug Profile: NEO-PV-01
  • Table 5.30. Drug Profile: NEO-PTC-01
  • Table 5.31. Drug Profile: NEO-SV-01
  • Table 5.32. Neon Therapeutics: Future Outlook
  • Table 6.1. Neoantigen Targeted Therapies: List of Publications, 2017-2018
  • Table 7.1. Patent Analysis: CPC Classification Symbol Definitions
  • Table 7.2. Patent Analysis: Popular CPC Classification Symbols
  • Table 7.3. Patent Analysis: List of Top CPC Classifications
  • Table 7.4. Patent Analysis: List of Leading Individual Assignees
  • Table 7.5. Patent Analysis: Benchmarking Analysis Summary
  • Table 7.6. Patent Analysis: List of Leading Patents (by Highest Relative Valuation)
  • Table 8.1. Neoantigen Targeted Therapies: Partnerships and Collaborations, 2014-2019
  • Table 9.1. Neoantigen Targeted Therapies: Funding and Investments, 2014-2019
  • Table 13.1. Neoantigen Targeted Therapies: Distribution by Phase of Development
  • Table 13.2. Neoantigen Targeted Therapies: Distribution by Type of Molecule
  • Table 13.3. Neoantigen Targeted Therapies: Distribution by Type of Immunotherapy
  • Table 13.4. Neoantigen Targeted Therapies: Distribution by Type of Therapy
  • Table 13.5. Neoantigen Targeted Therapies: Distribution by Route of Administration
  • Table 13.6. Neoantigen Targeted Therapies: Distribution by Target Disease Indication
  • Table 13.7. Neoantigen Targeted Therapies: Distribution by Type of Neoantigen
  • Table 13.8. Neoantigen Targeted Therapies: Distribution by Line of Therapy
  • Table 13.9. Neoantigen Targeted Therapies: Distribution by Year of Establishment of Developer
  • Table 13.10. Neoantigen Targeted Therapies: Distribution by Company Size and Geographical Location
  • Table 13.11. Leading Developers: Distribution by Number of Therapies
  • Table 13.12. Neoantigen Targeted Therapies: Distribution by Geographical Location
  • Table 13.13. Bavarian Nordic: Annual Revenues, FY2014-FY2018 (DKK Million)
  • Table 13.14. MediGene: Annual Revenues, FY2014-FY2018 (EUR Million)
  • Table 13.15. Publications: Year of Publication
  • Table 13.16. Publications: Distribution by Type of Study
  • Table 13.17. Publications: Distribution by Study Objective
  • Table 13.18. Publications: Distribution by Affiliated Therapies
  • Table 13.19. Publications: Distribution by Target Disease Indication
  • Table 13.20. Key Journals: Distribution by Number of Publications
  • Table 13.21. Patent Analysis: Distribution by Type of Patent
  • Table 13.22. Patent Analysis: Cumulative Distribution by Publication Year, Pre2010-2019
  • Table 13.23. Patent Analysis: Distribution by Geographical Location
  • Table 13.24. Patent Analysis: Distribution by Geographical Location, 2000-200 9 and 2010-2019
  • Table 13.25. Patent Analysis: Distribution by Type of Applicant
  • Table 13.26. Leading Industry Players: Distribution by Number of Patents
  • Table 13.27. Leading Non-Industry Players: Distribution by Number of Patents
  • Table 13.28. Patent Analysis: Leading Individual Assignees
  • Table 13.29. Patent Analysis: Distribution by Patent Age (January 2000 - April 2019)
  • Table 13.30. Patent Analysis: Valuation Analysis
  • Table 13.31. Partnerships and Collaborations: Cumulative Trend by Year, 2014-2019
  • Table 13.32. Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 13.33. Partnerships and Collaborations: Distribution by Type of Partnership, 2014-2016 and 2017-2019
  • Table 13.34. Partnerships and Collaborations: Distribution by Type of Product
  • Table 13.35. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Immunotherapy
  • Table 13.36. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Target Disease Indication
  • Table 13.37. Most Active Players: Distribution by Number of Partnerships
  • Table 13.38. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Table 13.39. Funding and Investments: Distribution by Type of Funding and Year of Establishment, 2014-2019
  • Table 13.40. Funding and Investments: Cumulative Number of Instances by Year, 2014-2019
  • Table 13.41. Funding and Investments: Distribution by Type of Funding and Year, 2014-2019
  • Table 13.42. Funding and Investments: Cumulative Amount Invested, 2014-2019 (USD Million)
  • Table 13.43. Funding and Investments: Distribution of Instances by Type of Funding, 2014-2019
  • Table 13.44. Funding and Investments: Distribution of the Total Amount Invested by Type of Funding, 2014-2019 (USD Million)
  • Table 13.45. Funding and Investments: Summary of Investments, 2014-2019 (USD Million)
  • Table 13.46. Funding and Investments: Analysis by Amount Invested across Different Types of Therapies
  • Table 13.47. Funding and Investments: Distribution by Amount Invested across Different Types of Indications
  • Table 13.48. Funding and Investments: Distribution by Geography
  • Table 13.49. Most Active Players: Distribution by Amount Invested (USD Million)
  • Table 13.50. Most Active Investors: Distribution by Number of Instances
  • Table 13.51. Funding and Investments Summary, 2014-2019 (USD Million)
  • Table 13.52. Global Neoantigen Targeted Therapies Market, 2019-2030 Base, Optimistic, Conservative Case (USD Billion)
  • Table 13.53. Global Neoantigen Targeted Therapies Market Distribution by Region, 2019-2030 (USD Million)
  • Table 13.54. Global Neoantigen Targeted Therapies Market: Distribution by Target Disease Indication, 2019-2030 (USD Million)
  • Table 13.55. Global Neoantigen Targeted Therapies Market for Bone and Cartilage Cancer, 2019-2030 (USD Million)
  • Table 13.56. Global Neoantigen Targeted Therapies Market for Colorectal Cancer, 2019-2030 (USD Million)
  • Table 13.57. Global Neoantigen Targeted Therapies Market for Gynecological Cancers, 2019-2030 (USD Million)
  • Table 13.58. Global Neoantigen Targeted Therapies Market for Head and Neck Cancer, 2019-2030 (USD Million)
  • Table 13.59. Global Neoantigen Targeted Therapies Market for Hepatocellular Carcinoma, 2019-2030 (USD Million)
  • Table 13.60. Global Neoantigen Targeted Therapies Market for Lung Cancer, 2019-2030 (USD Million)
  • Table 13.61. Global Neoantigen Targeted Therapies Market for Renal Carcinoma, 2019-2030
  • Table 13.62. Global Neoantigen Targeted Therapies Market for Other Cancers, 2019-2030 (USD Million)
  • Table 13.63. Global Neoantigen Targeted Therapies Market: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
  • Table 13.64. Global Neoantigen Targeted Therapies Market for Personalized Neoantigen Therapy, 2019-2030 (USD Million)
  • Table 13.65. Global Neoantigen Targeted Therapies Market for Off-the-shelf Neoantigen Therapy, 2019-2030 (USD Million)
  • Table 13.66. Global Neoantigen Targeted Therapies Market: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
  • Table 13.67. Global Neoantigen Targeted Therapies Market for Dendritic Cell Vaccines, 2019-2030 (USD Million)
  • Table 13.68. Global Neoantigen Targeted Therapies Market for DNA / RNA-based Vaccines, 2019-2030 (USD Million)
  • Table 13.69. Global Neoantigen Targeted Therapies Market for Protein / Peptide-based Vaccine, 2019-2030 (USD Million)
  • Table 13.70. Global Neoantigen Targeted Therapies Market for TIL-based Therapies, 2019-2030 (USD Million)
  • Table 13.71. Global Neoantigen Targeted Therapies Market: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Table 13.72. Global Neoantigen Targeted Therapies Market for Intradermal Route of Administration, 2019-2030 (USD Million)
  • Table 13.73. Global Neoantigen Targeted Therapies Market for Intravenous Route of Administration, 2019-2030 (USD Million)
  • Table 13.74. Global Neoantigen Targeted Therapies Market for Subcutaneous Route of Administration, 2019-2030 (USD Million)
  • Table 13.75. Global Neoantigen Targeted Therapies Market for Others Route of Administration, 2019-2030 (USD Million)
  • Table 13.76. Neoantigen Targeted Therapies Market in the US, 2019-2030, Base, Optimistic, Conservative Case (USD Million)
  • Table 13.77. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Target Disease Indication, 2019-2030 (USD Million)
  • Table 13.78. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
  • Table 13.79. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
  • Table 13.80. Neoantigen Targeted Therapies Market in the US: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Table 13.81. Neoantigen Targeted Therapies Market in the UK, 2019-2030, Base, Optimistic, Conservative Case (USD Million)
  • Table 13.82. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Target Disease Indication, 2019-2030 (USD Million)
  • Table 13.83. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
  • Table 13.84. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
  • Table 13.85. Neoantigen Targeted Therapies Market in the UK: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Table 13.86. Neoantigen Targeted Therapies Market in Germany, 2019-2030, Base, Optimistic, Conservative Case (USD Million)
  • Table 13.87. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Target Disease Indication, 2019-2030 (USD Million)
  • Table 13.88. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
  • Table 13.89. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
  • Table 13.90. Neoantigen Targeted Therapies Market in Germany: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Table 13.91. Neoantigen Targeted Therapies Market in France, 2019-2030, Base, Optimistic, Conservative Case (USD Million)
  • Table 13.92. Neoantigen Targeted Therapies Market in France: Distribution by Type of Target Disease Indication, 2019-2030 (USD Million)
  • Table 13.93. Neoantigen Targeted Therapies Market in France: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
  • Table 13.94. Neoantigen Targeted Therapies Market in France: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
  • Table 13.95. Neoantigen Targeted Therapies Market in France: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Table 13.96. Neoantigen Targeted Therapies Market in Italy, 2019-2030, Base, Optimistic, Conservative Case (USD Million)
  • Table 13.97. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Target Disease Indication, 2019-2030 (USD Million)
  • Table 13.98. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
  • Table 13.99. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
  • Table 13.100. Neoantigen Targeted Therapies Market in Italy: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Table 13.101. Neoantigen Targeted Therapies Market in Spain, 2019-2030, Base, Optimistic, Conservative Case (USD Million)
  • Table 13.102. Neoantigen Targeted Therapies Market in Spain: Distribution by Target Disease Indication, 2019-2030 (USD Million)
  • Table 13.103. Neoantigen Targeted Therapies Market in Spain: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
  • Table 13.104. Neoantigen Targeted Therapies Market in Spain: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
  • Table 13.105. Neoantigen Targeted Therapies Market in Spain: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Table 13.106. Neoantigen Targeted Therapies Market in Rest of the World, Base, Optimistic, Conservative Case, 2019-2030 (USD Million)
  • Table 13.107. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of Target Disease Indication, 2019-2030 (USD Million)
  • Table 13.108. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
  • Table 13.109. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
  • Table 13.110. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Route of Administration, 2019-2030 (USD Million)

Listed Companies

The following companies and organizations have been mentioned in the report:

  • 1. 5AM Ventures
  • 2. AbbVie Ventures
  • 3. Abingworth
  • 4. Abu Dhabi Investment Authority
  • 5. Accelerate NY Seed Fund
  • 6. Accelovance
  • 7. Access Industries
  • 8. Achilles Therapeutics
  • 9. Adage Capital Management
  • 10. Adaptive Biotechnologies
  • 11. Aduro Biotech
  • 12. Advaxis
  • 13. Agalimmune
  • 14. Agenus
  • 15. Ageo Central General Hospital
  • 16. Agreen Biotech
  • 17. Aisling Capital
  • 18. AIVITA Biomedical
  • 19. Albion Capital
  • 20. Alexandria Venture Investments
  • 21. Alexion Pharmaceuticals
  • 22. Allscripts
  • 23. AMAL Therapeutics
  • 24. Amgen
  • 25. Amgen Ventures
  • 26. Andera Partners
  • 27. Apexigen
  • 28. Arbutus Biopharma
  • 29. ARCH Venture Partners
  • 30. Arcus Biosciences
  • 31. ArrowMark Partners
  • 32. Asia Genomics
  • 33. Astellas Pharma
  • 34. AstraZeneca
  • 35. AT Impf
  • 36. Atlas Venture
  • 37. Baillie Gifford
  • 38. Bain Capital Life Sciences
  • 39. Bavarian Nordic
  • 40. BB Biotech
  • 41. Beth Israel Deaconess Medical Center
  • 42. BGI Americas
  • 43. Bill & Melinda Gates Foundation
  • 44. BioClub
  • 45. BioLife Solutions
  • 46. BioLineRx
  • 47. BioMedPartners
  • 48. BioNJ
  • 49. BioNTech
  • 50. BlackBerry Partners Fund
  • 51. Blackstone
  • 52. bluebird bio
  • 53. Boehringer Ingelheim Venture Fund
  • 54. Bpifrance
  • 55. BrightPath Biotherapeutics
  • 56. Bristol-Myers Squibb
  • 57. Broad Institute
  • 58. Broadfin Capital
  • 59. Button Capital
  • 60. BVF Partners
  • 61. Caladrius Biosciences
  • 62. California Technology Ventures
  • 63. Canaan Investment
  • 64. Cancer Prevention and Research Institute of Texas
  • 65. Cancer Research Technology
  • 66. Casdin Capital
  • 67. Catalent
  • 68. Celgene
  • 69. Cellular Biomedicine
  • 70. Charles River Laboratories
  • 71. Chartwave
  • 72. Children's Hospital of Orange County
  • 73. China Medical System
  • 74. Clal Biotechnology Industries
  • 75. Clarus Ventures
  • 76. Clough Capital Partners
  • 77. Comecer
  • 78. Cormorant Asset Management
  • 79. CRISPR Therapeutics
  • 80. Cryoport
  • 81. CTI Life Sciences
  • 82. CureVac
  • 83. CyTIX
  • 84. Cytovance Biologics
  • 85. Dana-Farber Cancer Institute
  • 86. DATUM
  • 87. Decheng Capital
  • 88. dievini Hopp Biotech
  • 89. Droia Oncology Ventures
  • 90. EcoR1 Capital
  • 91. EDBI
  • 92. Effimune
  • 93. EIC SME Instrument
  • 94. Eli Lilly
  • 95. ELMA Investments
  • 96. EMD Millipore
  • 97. EpiVax Oncology
  • 98. EUFETS
  • 99. European Investment Bank
  • 100. Evaxion Biotech
  • 101. Fidelity Investments
  • 102. Flow Pharma
  • 103. Forbion
  • 104. Foresite Capital
  • 105. F-Prime Capital
  • 106. Franklin Advisers
  • 107. Frazier Healthcare Partners
  • 108. Genentech
  • 109. Geneos Therapeutics
  • 110. Genocea Biosciences
  • 111. Georgetown University
  • 112. GlobeImmune
  • 113. Gradalis
  • 114. Grey Wolf Therapeutics
  • 115. Gritstone Oncology
  • 116. Google Ventures
  • 117. Hangzhou Neoantigen Therapeutics
  • 118. Heat Biologics
  • 119. Helmholtz Zentrum München
  • 120. Helsinn Group
  • 121. HengRui YuanZheng Biotechnology
  • 122. Hercules Capital
  • 123. High-Tech Gründerfonds
  • 124. Hillhouse Capital Group
  • 125. Icahn School of Medicine at Mount Sinai
  • 126. IDG Capital
  • 127. Immatics
  • 128. Immune Design
  • 129. Immunicum
  • 130. ImmuNext
  • 131. Immunomic Therapeutics
  • 132. Immunovative Therapies
  • 133. IMV Technologies
  • 134. Infinity Pharmaceuticals
  • 135. Innovate UK
  • 136. Innovation Fund Denmark
  • 137. Inovio Pharmaceuticals
  • 138. Institut Mérieux
  • 139. Intrexon
  • 140. Investsud
  • 141. Iovance Biotherapeutics
  • 142. ISA Pharmaceuticals
  • 143. Janssen Pharmaceuticals
  • 144. Janus Capital Management
  • 145. Janus Henderson Investors
  • 146. Jennison Associates
  • 147. Johnson & Johnson Development
  • 148. Kanagawa Cancer Center
  • 149. Karolinska University Hospital
  • 150. Keiretsu Forum
  • 151. Khoen Ken Medical Center
  • 152. Kuwait Investment Authority
  • 153. La Jolla Institute for Allergy and Immunology
  • 154. Leerink Partners
  • 155. Leiden University Medical Center
  • 156. Level One Partners
  • 157. Likang Life Sciences
  • 158. Lilly Asia Ventures
  • 159. LSP
  • 160. Massachusetts General Hospital
  • 161. MaSTherCell
  • 162. Mateon Therapeutics
  • 163. Max Delbrück Center for Molecular Medicine in the Helmholtz Association
  • 164. MD Anderson Cancer Center
  • 165. Medigene
  • 166. MedImmune
  • 167. Meir Medical Center
  • 168. Memorial Sloan Kettering Cancer Center
  • 169. Merck
  • 170. Meusinvest
  • 171. Mie University
  • 172. Miller Value Partners
  • 173. Miracle Light Incubator
  • 174. Moderna Therapeutics
  • 175. Moffitt Cancer Center
  • 176. Morningside Group
  • 177. MSD Partners
  • 178. NantBioScience
  • 179. NantCell
  • 180. NantWorks
  • 181. Natera
  • 182. National Institutes of Health
  • 183. Natixis
  • 184. NEC
  • 185. Nektar Therapeutics
  • 186. Neon Therapeutics
  • 187. NeoPhore
  • 188. Netherlands Cancer Institute
  • 189. NexImmune
  • 190. Nextech Invest
  • 191. NextWavebio
  • 192. Norwegian Cancer Society
  • 193. Nouscom
  • 194. Novartis
  • 195. Novartis Institutes for BioMedical Research
  • 196. Ohio State University Comprehensive Cancer Center
  • 197. Omega Funds
  • 198. Omeros
  • 199. OncoImmunity
  • 200. Oncos Therapeutics
  • 201. OncoSec Medical
  • 202. Oncotest-Teva
  • 203. OPKO Health
  • 204. OrbiMed Advisors
  • 205. ORYX Translational Medicine
  • 206. OSE Immunotherapeutics
  • 207. PACT Pharma
  • 208. Parker Institute for Cancer Immunotherapy
  • 209. Partner Fund Management
  • 210. Paulson Capital
  • 211. PCI Biotech
  • 212. PDC*line Pharma
  • 213. Pelican Therapeutics
  • 214. Perceptive Advisors
  • 215. Persimmune
  • 216. Pfizer
  • 217. Pfizer Ventures
  • 218. PharmaCell
  • 219. Pharmaceutical Product Development
  • 220. Pharmstandard International
  • 221. Phio Pharmaceuticals
  • 222. PhosImmune
  • 223. Phyton Biotech
  • 224. Pictet
  • 225. PolyBioCept
  • 226. Pontifax
  • 227. Precigen
  • 228. Precision BioLogic
  • 229. ProBioGen
  • 230. Quogue Capital
  • 231. RA Capital Management
  • 232. Redmile Group
  • 233. Regeneron Pharmaceuticals
  • 234. Replimune
  • 235. Roche
  • 236. RTW Investments
  • 237. Ruffer
  • 238. Rutgers Cancer Institute
  • 239. Sailing Capital
  • 240. Sanquin Blood Supply Foundation
  • 241. Santé Ventures
  • 242. Schroder Adveq
  • 243. SciVac Therapeutics
  • 244. Sectoral Asset Management
  • 245. Sequoia Capital China
  • 246. SGI-DNA
  • 247. Shenzhen Yuce Biotechnology
  • 248. Siemens
  • 249. SIGMA Group
  • 250. Sixth Element Capital
  • 251. Sorgente
  • 252. Spinventure
  • 253. Square 1 Bank
  • 254. Stand Up To Cancer
  • 255. Stanford University
  • 256. Stemirna Therapeutics
  • 257. Structured Immunity
  • 258. Struengmann Family Office
  • 259. Sygnature Discovery
  • 260. Syncona
  • 261. SYZ Cell Therapy
  • 262. T. Rowe Price Associates
  • 263. Taiho Pharmaceutical
  • 264. Taiho Ventures
  • 265. Targovax
  • 266. tella
  • 267. Texas Oncology
  • 268. The Column Group
  • 269. The Francis Crick Institute
  • 270. The Invus Group
  • 271. The Research Council of Norway
  • 272. Third Rock Ventures
  • 273. ThorgeneNeo
  • 274. TrakCel
  • 275. Transformational Healthcare Venture Capital
  • 276. Transgene
  • 277. Trianta Immunotherapies
  • 278. Trinitas Capital Management
  • 279. Turnstone Biologics
  • 280. UConn Health
  • 281. University College London
  • 282. University Hospital Southampton NHS Foundation Trust
  • 283. University of Colorado
  • 284. University of Lausanne
  • 285. University of North Carolina
  • 286. University of Washington
  • 287. Vaccibody
  • 288. Vaxil Bio therapeutics
  • 289. VAXIMM
  • 290. VAXON Biotech
  • 291. VBI Vaccines
  • 292. Vedantra Pharmaceuticals
  • 293. Verizon
  • 294. Versant Ventures
  • 295. Viking Global Investors
  • 296. Wallonia Biotech Coaching
  • 297. Washington University School of Medicine
  • 298. Wellington Partners
  • 299. WhiteRock Capital Partners
  • 300. Wu Capital Group
  • 301. Wuhan Dangdai Science & Technology Industries
  • 302. WuXi AppTec
  • 303. Yale Cancer Center
  • 304. Zelluna Immunotherapy
  • 305. Ziopharm Oncology
Back to Top